Erytech Pharma SA Performance
| ERYPDelisted Stock | USD 0.78 0.04 4.88% |
The firm shows a Beta (market volatility) of -0.27, which means not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Erytech Pharma are expected to decrease at a much lower rate. During the bear market, Erytech Pharma is likely to outperform the market. Erytech Pharma SA right now shows a risk of 0.0%. Please confirm Erytech Pharma SA value at risk, rate of daily change, as well as the relationship between the Rate Of Daily Change and relative strength index , to decide if Erytech Pharma SA will be following its price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Erytech Pharma SA has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable basic indicators, Erytech Pharma is not utilizing all of its potentials. The newest stock price agitation, may contribute to short-term losses for the retail investors. ...more
| Begin Period Cash Flow | 33.7 M |
Erytech |
Erytech Pharma Relative Risk vs. Return Landscape
If you would invest 78.00 in Erytech Pharma SA on September 1, 2024 and sell it today you would earn a total of 0.00 from holding Erytech Pharma SA or generate 0.0% return on investment over 90 days. Erytech Pharma SA is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Erytech, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Erytech Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Erytech Pharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Erytech Pharma SA, and traders can use it to determine the average amount a Erytech Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| ERYP |
Based on monthly moving average Erytech Pharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Erytech Pharma by adding Erytech Pharma to a well-diversified portfolio.
Erytech Pharma Fundamentals Growth
Erytech Stock prices reflect investors' perceptions of the future prospects and financial health of Erytech Pharma, and Erytech Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Erytech Stock performance.
| Return On Equity | -0.0098 | |||
| Return On Asset | -0.3 | |||
| Profit Margin | (0.03) % | |||
| Operating Margin | (4.08) % | |||
| Current Valuation | 211.16 K | |||
| Shares Outstanding | 34.12 M | |||
| Price To Earning | (5.88) X | |||
| Price To Book | 0.65 X | |||
| Price To Sales | 7.58 X | |||
| EBITDA | (22.69 M) | |||
| Cash And Equivalents | 54.05 M | |||
| Cash Per Share | 1.74 X | |||
| Total Debt | 13.57 M | |||
| Debt To Equity | 1.00 % | |||
| Book Value Per Share | 0.76 X | |||
| Cash Flow From Operations | (31.76 M) | |||
| Earnings Per Share | (0.01) X | |||
| Total Asset | 45.81 M | |||
| Retained Earnings | (228 K) | |||
| Current Asset | 94.53 M | |||
| Current Liabilities | 9.8 M | |||
About Erytech Pharma Performance
Assessing Erytech Pharma's fundamental ratios provides investors with valuable insights into Erytech Pharma's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Erytech Pharma is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. The company was incorporated in 2004 and is headquartered in Lyon, France. Erytech Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 149 people.Things to note about Erytech Pharma SA performance evaluation
Checking the ongoing alerts about Erytech Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Erytech Pharma SA help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Erytech Pharma SA is not yet fully synchronised with the market data | |
| Erytech Pharma SA has some characteristics of a very speculative penny stock | |
| Erytech Pharma SA has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (228 K) with profit before overhead, payroll, taxes, and interest of 4.18 M. | |
| Erytech Pharma SA currently holds about 54.05 M in cash with (31.76 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.74, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing Erytech Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Erytech Pharma's stock is overvalued or undervalued compared to its peers.
- Examining Erytech Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Erytech Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Erytech Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Erytech Pharma's stock. These opinions can provide insight into Erytech Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Other Consideration for investing in Erytech Stock
If you are still planning to invest in Erytech Pharma SA check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Erytech Pharma's history and understand the potential risks before investing.
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios |